In the absence of an effective and safe vaccine against HIV-1, the administration of broadly
neutralizing antibodies (bNAbs) represents a logical alternative approach to prevent virus …

Highly potent and broadly neutralizing anti-HIV-1 antibodies (bNAbs) have been used to
prevent and treat lentivirus infections in humanized mice, macaques, and humans,,,,,,,,,,,. In …

HIV-1 sequence diversity presents a major challenge for the clinical development of broadly
neutralizing antibodies (bNAbs) for both therapy and prevention. Sequence variation in …

Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency
virus type 1 (HIV-1) infection, little progress has been made in generating an effective HIV-1 …

Broadly neutralizing antibodies (BnAbs) protect macaques from cell-free simian/human
immunodeficiency virus (SHIV) challenge, but their efficacy against cell-associated SHIV is …

The fusion peptide (FP) on the HIV-1 envelope (Env) trimer can be targeted by broadly
neutralizing antibodies (bNAbs). Here, we evaluated the ability of a human FP-directed …

Abstract The Antibody Mediated Prevention trials showed that the broadly neutralizing
antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) …

Neutralizing antibodies are thought to be crucial for HIV vaccine protection, but studies in
animal models suggest that high antibody concentrations are required. This is a major …

Broadly neutralizing antibodies (bNAbs) have demonstrated protective effects against HIV-1
in primate studies and recent human clinical trials. Elite neutralizers are potential candidates …

Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the
treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of …